Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Coffey

Showing results (31-40 of 48) with videos related to

Pageof 5
Sort By:
Movement Disorders : Official Journal of the Movement Disorder Society|March 5, 2015
Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's diseaseDaniel Weintraub, Tanya Simuni, Chelsea Caspell-Garcia, et al.
Annals of Clinical and Translational Neurology|March 11, 2026
Five-Year Disease Progression in Synuclein Seeding Positive Sporadic Parkinson's DiseasePaulina Gonzalez-Latapi, Caroline Gochanour, Seung Ho Choi, et al.
NPJ Parkinson'S Disease|February 28, 2023
LRRK2 and GBA1 variant carriers have higher urinary bis(monacylglycerol) phosphate concentrations in PPMI cohortsKalpana M Merchant, Tanya Simuni, Janel Fedler, et al.
Lancet (London, England)|March 2, 2024
National, regional, and global estimates of low birthweight in 2020, with trends from 2000: a systematic analysisYemisrach B Okwaraji, Julia Krasevec, Ellen Bradley, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|April 30, 2025
Neuronal α-Synuclein Disease Stage Progression over 5 YearsTanya Simuni, Caroline Gochanour, Anuprita R Nair, et al.
Parkinsonism & Related Disorders|February 11, 2019
Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI)Neha Prakash, Chelsea Caspell-Garcia, Christopher Coffey, et al.
SAGE Open Medicine|November 1, 2024
Negative effect of treatment with mGluR5 negative allosteric modulator AFQ056 on blood biomarkers in young individuals with Fragile X syndromeDragana Protic, Elizabeth Breeze, Guadalupe Mendoza, et al.
Medrxiv : the Preprint Server for Health Sciences|December 23, 2024
Impact of dopamine deficiency and REM sleep behavior disorder on cognition in early neuronal synuclein disease with hyposmiaDaniel Weintraub, Anuprita R Nair, Ryan Kurth, et al.
Plos One|May 19, 2017
Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson diseaseChelsea Caspell-Garcia, Tanya Simuni, Duygu Tosun-Turgut, et al.
Annals of Clinical and Translational Neurology|December 15, 2020
Dopamine transporter imaging predicts clinically-defined α-synucleinopathy in REM sleep behavior disorderLana M Chahine, Michael C Brumm, Chelsea Caspell-Garcia, et al.
Pageof 5

Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
Movement Disorders : Official Journal of the Movement Disorder Society|March 5, 2015
Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's diseaseDaniel Weintraub, Tanya Simuni, Chelsea Caspell-Garcia, et al.
Annals of Clinical and Translational Neurology|March 11, 2026
Five-Year Disease Progression in Synuclein Seeding Positive Sporadic Parkinson's DiseasePaulina Gonzalez-Latapi, Caroline Gochanour, Seung Ho Choi, et al.
NPJ Parkinson'S Disease|February 28, 2023
LRRK2 and GBA1 variant carriers have higher urinary bis(monacylglycerol) phosphate concentrations in PPMI cohortsKalpana M Merchant, Tanya Simuni, Janel Fedler, et al.
Lancet (London, England)|March 2, 2024
National, regional, and global estimates of low birthweight in 2020, with trends from 2000: a systematic analysisYemisrach B Okwaraji, Julia Krasevec, Ellen Bradley, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|April 30, 2025
Neuronal α-Synuclein Disease Stage Progression over 5 YearsTanya Simuni, Caroline Gochanour, Anuprita R Nair, et al.
Parkinsonism & Related Disorders|February 11, 2019
Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI)Neha Prakash, Chelsea Caspell-Garcia, Christopher Coffey, et al.
SAGE Open Medicine|November 1, 2024
Negative effect of treatment with mGluR5 negative allosteric modulator AFQ056 on blood biomarkers in young individuals with Fragile X syndromeDragana Protic, Elizabeth Breeze, Guadalupe Mendoza, et al.
Medrxiv : the Preprint Server for Health Sciences|December 23, 2024
Impact of dopamine deficiency and REM sleep behavior disorder on cognition in early neuronal synuclein disease with hyposmiaDaniel Weintraub, Anuprita R Nair, Ryan Kurth, et al.
Plos One|May 19, 2017
Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson diseaseChelsea Caspell-Garcia, Tanya Simuni, Duygu Tosun-Turgut, et al.
Annals of Clinical and Translational Neurology|December 15, 2020
Dopamine transporter imaging predicts clinically-defined α-synucleinopathy in REM sleep behavior disorderLana M Chahine, Michael C Brumm, Chelsea Caspell-Garcia, et al.
Pageof 5